Project Grant R01DA065785
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $422,125 in funding through its Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Nebraska Medical Center to conduct epidemiological research on oral nicotine pouch (ONP) use among adolescents and young adults (AYAs). The award, effective July 1, 2026 through June 30, 2028, supports a two-year study harmonizing nationally representative survey and biomarker data from waves 7-9...
- Federal Grant Award Summary Health Research, Inc. (Roswell Park Division) received a $816,307 Project Grant award, effective September 15, 2025, through August 31, 2030, under the Family Smoking Prevention and Tobacco Control Act (TCA) Regulatory Research program (CFDA 93.077). This research project, conducted at the awardee's Buffalo, New York facility, generates scientific evidence to inform the Food and Drug Administration's regulatory authority over tobacco products by assessing the market...
- Federal Grant Award Summary The University of California, San Francisco received a $127,168 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026 through March 31, 2028. The award supports research investigating the effects of e-cigarettes, with and without menthol, on vascular endothelial cell health in African American populations, with particular focus on how Apolipoprotein L1...
- Federal Grant Award Summary The National Institutes of Health, administering funds through the FDA Center for Tobacco Products under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded The Ohio State University a K01 mentored career development project grant of $186,281 on August 1, 2025, with a completion date of July 31, 2030. This award funds a novel research study investigating the abuse liability and substitutability of synthetic coolants...
- Federal Grant Award Summary Oregon Health & Science University received a $905,044 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 1, 2026 through April 30, 2028. This mixed-methods research study will examine current practices and barriers related to electronic nicotine delivery systems (ENDS) use assessment and cessation assistance in primary care settings across 22 clinics serving over 154,000...
- Federal Project Grant Award Summary Health Research, Inc.'s Roswell Park Division was awarded $347,000 by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) on July 8, 2026, with a completion date of July 7, 2028. The award funds a large-scale, population-based research study examining the impact of reduced-exposure nicotine products on oral health conditions among high-risk populations in the United States....
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $1.9M to the University of Nevada, Reno under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a human laboratory study examining how "natural" descriptors on cigarillo packaging influence consumer expectancies, subjective effects, smoking behavior, and toxicant exposure among young adult users. The five-year project (September 15, 2025–May 31, 2030) addresses a significant regulatory...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the Research Foundation For Mental Hygiene, Inc. (operating through the New York State Psychiatric Institute) a Project Grant totaling $195,804 under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period August 1, 2026 through July 31, 2031. This research project investigates the effects of cannabis on nicotine use patterns, specifically examining how cannabis influences electronic nicotine...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $247,878 Project Grant to the University of Texas at Arlington effective May 1, 2026, through April 30, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This research initiative investigates the impact of waterpipe tobacco smoking configurations on toxicant exposure, user behavior, and abuse liability among young adults. The project addresses a significant public health concern, as...
- Federal Project Grant Award Summary The University of Louisville's Office of Research & Innovation received a $782,293 Project Grant awarded June 10, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), funded by the National Institutes of Health Office of the Director. The award supports a five-year research initiative (through May 31, 2031) investigating cardiorespiratory and autonomic nervous system impacts of coolants—including...
The National Institutes of Health Office of the Director awarded $819,998 to The Regents of the University of California, San Francisco under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) on August 1, 2026, with a completion date of July 31, 2029. This clinical pharmacology research project will investigate the human health effects and nicotine exposure profiles associated with oral nicotine pouches (ONPs), which are FDA-authorized tobacco products that have experienced significant growth in popularity among both adults and youth in the United States. The research addresses a critical knowledge gap, as most prior studies of ONP pharmacology have been industry-sponsored single-dose investigations, leaving substantial uncertainty regarding the absolute risks of regular ONP use, particularly among never-smokers and users who may titrate their nicotine intake throughout the day. The project will deliver comparative clinical pharmacology data through two primary research initiatives: (1) examination of nicotine exposure levels and subjective effects from ONP use at varying nicotine concentrations (0 mg, 3 mg, and 6 mg) compared to cigarette smoking and vaping; and (2) assessment of acute cardiovascular effects including hemodynamic, vascular, and immunological impacts. These independent research findings will provide the scientific evidence base necessary to support FDA's regulatory authority and inform public health policy decisions regarding ONP marketing authorization and potential restrictions, thereby addressing the regulatory research priorities established under the Family Smoking Prevention and Tobacco Control Act.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $820.0k | 7/17/26 |